MedTrace Logo

11C- and 18F-Choline PET/MR Imaging for Prostate Cancer

NCT02397408 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2020-11-19

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well 11C-choline (carbon C 11 choline) and 18F-choline (fluorine F 18 choline) positron emission tomography/magnetic resonance (PET/MR) imaging works in diagnosing patients with unfavorable intermediate to high-risk prostate cancer. Diagnostic procedures, such as 11C- and 18F-choline PET/MR may help find and diagnose prostate cancer and find out how far the disease has spread.

Conditions

Interventions

DRUG

Carbon C 11 Choline

Given intravenously (IV) prior to imaging

DRUG

Fluorine F 18 Choline

Given intravenously (IV) prior to imaging

PROCEDURE

Positron Emission Tomography (PET) / Magnetic Resonance Imaging (MRI)

Undergo whole-body PET/MR imaging

Sponsors & Collaborators

Principal Investigators

  • Albert J Chang, MD, PhD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-09
Primary Completion
2015-06-30
Completion
2015-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02397408 on ClinicalTrials.gov